NOVEL SARS-COV-2 PANDEMIC TRANSMISSION WITH ONGOING ANTIVIRAL THERAPIES AND VACCINE DESIGN

被引：0

作者：

Yameen, Muhammad ^{[1
]}

Sattar, Sara ^{[3
]}

Khalid, Ayesha ^{[3
]}

Aslam, Muhammad Aamir ^{[2
]}

Zafar, Nishat ^{[2
]}

Saeed, Muhammad Hassan ^{[4
]}

Arif, Muhammad Haseeb ^{[4
]}

Jahangeer, Muhammad ^{[1
]}

Qadeer, Azka ^{[2
]}

Hussain, Shoukat ^{[1
]}

Aamir, Muhammad ^{[2
]}

Mukhtar, Sania ^{[2
]}

Nasir, Huma ^{[2
]}

Shahzad, Asif ^{[1
]}

机构：

[1] Govt Coll Univ, Dept Biochem, Faisalabad 38000, Pakistan

[2] Univ Agr Faisalabad, Inst Microbiol, Faisalabad 38000, Pakistan

[3] COMSATS Univ Islamabad, Dept Biosci, Islamabad, Pakistan

[4] Univ Punjab, Dept Microbiol & Mol Genet, Lahore, Pakistan

来源：

ADVANCEMENTS OF MICROBIOLOGY | 2021年 / 60卷 / 01期

关键词：

SARs-CoV-2; WHO; viral genome; COVID-19; SARS-COV; CORONAVIRUS; COVID-19; MERS;

D O I：

10.21307/PM-2021.60.1.02

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Starting from the end of 2019 the new SARs-CoV-2 virus, in the period of a few months, had spread to 210 countries and its territories. The Wuhan wild animal market, in Hubei province, China is considered the epicenter of this pandemic. WHO declared the name COVID-19 to designate the disease caused by the SARS-CoV-2 virus. It is the third coronavirus pandemic after SARS in 2002-2003 and MERS-CoV in 2012. Genome sequencing of this new COVID-19/SARS-CoV-2 virus shows slight genetic diversity when compared to other coronaviruses. Owing to its pathogenesis, and less known replication cycle, no universal antiviral treatment can be applied and vaccine preparation is still a larger challenge. The present article will highlight transmission, pandemic status, genetic diversity current antiviral therapy, and vaccine trials for COVID-19.

引用

下载

页码：13 / 20

页数：8

共 50 条

[21] The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
Yu, Haiyun
Guan, Fei
Miller, Heather
Lei, Jiahui
Liu, Chaohong
EMERGING MICROBES & INFECTIONS, 2023, 12 (01)
[22] Implications of the Novel Mutations in the SARS-CoV-2 Genome for Transmission, Disease Severity, and the Vaccine Development
Akkiz, Hikmet
FRONTIERS IN MEDICINE, 2021, 8
[23] Designed for a pandemic: Mitigating the risk of SARS-CoV-2 transmission through hospital design and infrastructure
Kennedy, Brendan
Ashokan, Anushia
Lim, Chuan Kok
Lagana, Diana
Juraja, Marija
Shaw, David
INFECTION DISEASE & HEALTH, 2024, 29 (01) : 25 - 31
[24] Adaptation-Proof SARS-CoV-2 Vaccine Design
Vishweshwaraiah, Yashavantha L.
Hnath, Brianna
Rackley, Brendan
Wang, Jian
Gontu, Abhinay
Chandler, Morgan
Afonin, Kirill A.
Kuchipudi, Suresh, V
Christensen, Neil
Yennawar, Neela H.
Dokholyan, Nikolay, V
ADVANCED FUNCTIONAL MATERIALS, 2022, 32 (49)
[25] Novel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, Erik
Kronig, Ilona
Neher, Richard A.
Eckerle, Isabella
Vetter, Pauline
Kaiser, Laurent
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (08) : 1109 - 1117
[26] Design, production and characterization of antiviral proteins targeting SARS-CoV-2
Parreiras, S.
Cruz, C. H.
Valerio, M.
Sousa, P. M. F.
Soares, C. M.
Vicente, J. B.
Lousa, D.
FEBS OPEN BIO, 2022, 12 : 160 - 160
[27] SARS-CoV-2 mucosal vaccine
Stephanie Houston
Nature Immunology, 2023, 24 : 1 - 1
[28] Inactivated vaccine for SARS-CoV-2
Emma Risson
Nature Reviews Immunology, 2020, 20 : 353 - 353
[29] SARS-CoV-2 mucosal vaccine
Houston, Stephanie
NATURE IMMUNOLOGY, 2023, 24 (01) : 1 - 1
[30] A VACCINE AGAINST SARS-COV-2
Passi, Gouri Rao
INDIAN PEDIATRICS, 2020, 57 (06) : 593 - 593

← 1 2 3 4 5 →